- Home
- FSHP vs JSPR Comparison
FSHP vs JSPR Comparison
Compare FSHP & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- JSPR
- Stock Information
- Founded
- FSHP 2018
- JSPR 2018
- Country
- FSHP United States
- JSPR United States
- Employees
- FSHP N/A
- JSPR N/A
- Industry
- FSHP
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSHP
- JSPR Health Care
- Exchange
- FSHP NYSE
- JSPR Nasdaq
- Market Cap
- FSHP 90.7M
- JSPR 85.8M
- IPO Year
- FSHP 2024
- JSPR N/A
- Fundamental
- Price
- FSHP $10.33
- JSPR $5.38
- Analyst Decision
- FSHP
- JSPR Strong Buy
- Analyst Count
- FSHP 0
- JSPR 11
- Target Price
- FSHP N/A
- JSPR $62.50
- AVG Volume (30 Days)
- FSHP 3.5K
- JSPR 363.3K
- Earning Date
- FSHP 01-01-0001
- JSPR 02-27-2025
- Dividend Yield
- FSHP N/A
- JSPR N/A
- EPS Growth
- FSHP N/A
- JSPR N/A
- EPS
- FSHP 0.17
- JSPR N/A
- Revenue
- FSHP N/A
- JSPR N/A
- Revenue This Year
- FSHP N/A
- JSPR N/A
- Revenue Next Year
- FSHP N/A
- JSPR N/A
- P/E Ratio
- FSHP $62.48
- JSPR N/A
- Revenue Growth
- FSHP N/A
- JSPR N/A
- 52 Week Low
- FSHP $9.99
- JSPR $4.55
- 52 Week High
- FSHP $10.33
- JSPR $31.01
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- JSPR 35.41
- Support Level
- FSHP N/A
- JSPR $5.02
- Resistance Level
- FSHP N/A
- JSPR $5.64
- Average True Range (ATR)
- FSHP 0.00
- JSPR 0.44
- MACD
- FSHP 0.00
- JSPR 0.19
- Stochastic Oscillator
- FSHP 0.00
- JSPR 26.45
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.